Previous 10 | Next 10 |
AMGEN ANNOUNCES RESULTS FROM TWO OPEN LABEL EXTENSION STUDIES OF REPATHA® (EVOLOCUMAB) PR Newswire Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 ...
Amgen (NASDAQ:AMGN) is scheduled to announce Q1 earnings results on Wednesday, April 27th, after market close. The consensus EPS Estimate is $4.16 (+12.4% Y/Y) and the consensus Revenue Estimate is $6.15B (+4.2% Y/Y). Over the last 2 years, AMGN has beaten EPS estimates 88% of the time and ha...
The stock market came into the new week with some ongoing concerns about the future, but at least among growth investors, the mood wasn't as bad as it was last week. As of 2 p.m. ET on Monday, the Nasdaq Composite (NASDAQINDEX: ^IXIC) managed to eliminate all of its losses and poke ...
Promising industry prospects and company quality are two components that are vital to successful long-term investing. If an industry isn't able to steadily grow, stocks in that industry likely won't either. And quality is important because below-average stocks in fast-growing industries oft...
Demand for COVID-19 vaccines and therapies helped contribute to a 12% increase in spending on medicines in the U.S. in 2021, according to the IQVIA Institute for Human Data Science. U.S. spending on medicines reached $407B last year, with COVID-19 vaccines and therapeutics adding $29B to that...
AMGEN ANNOUNCES WEBCAST OF 2022 FIRST QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , April 22, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Wednesday, April 27, 2022 ...
Many investors are looking to dial back their portfolio's overall risk and ramp up its income-producing potential right now. The market is moving into what's historically a tepid time of the year for stocks and this year we're moving into the slow summertime with an overhang of uncertai...
We are long-term, patient, and active value investors. Our mission is to be responsible stewards in our clients’ financial lives. Our objective is to seek long-term growth of capital. Within the O'Keeffe Stevens portfolio, positions thought to have aligned management teams were...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alnylam ( ALNY ): pioneering a new class of therapeutics based on RNA interference and a better fit for collaboration partner Novartis (NYSE: NVS ) BioMarin (NASDAQ: BMRN ): a rare disease gene therapy ...
Amgen Q4 2022 revenue was up 3% y/y. Cancer therapy Lumakras is a new revenue driver. Pipeline should drive growth for the rest of the decade. For further details see: Amgen's Cancer Portfolio And Pipeline Make It A Buy
News, Short Squeeze, Breakout and More Instantly...
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.01% on an annualized basis producing an average annual return of 8.86%....
2024-05-31 13:22:01 ET Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts project significant growth in this sector, with Amgen among key players like Novo Nordisk and Eli Lilly. The U.S. FDA has approved Amge...
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDA...